(Q38438554)

3 September 2017

title

Long-term effects of insulin glargine on the risk of breast cancer (English)

1 reference

3 September 2017

1 reference

1 reference

1 reference

S Suissa

1

1 reference

3 September 2017

L Azoulay

2

1 reference

3 September 2017

S Dell'Aniello

3

1 reference

3 September 2017

M Evans

4

1 reference

3 September 2017

J Vora

5

1 reference

3 September 2017

M Pollak

6

1 reference

3 September 2017

publication date

26 May 2011

1 reference

3 September 2017

1 reference

3 September 2017

volume

54

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

2254-2262

1 reference

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

The IGF-I receptor in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Insulin glargine and malignancy: an unwarranted alarm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Diabetes therapy and cancer risk: causal effects and other plausible explanations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Hormone replacement therapy use and variations in the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Insulin receptor expression by human prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Monomeric insulins obtained by protein engineering and their medical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

Transient Increase in the Risk of Breast Cancer after Giving Birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2190-9

The UK General Practice Research Database

21 January 2018

1 reference

12 December 2020

Insufficient evaluation of adverse events is not a proof of safety

1 reference

12 December 2020

Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency

1 reference

12 December 2020

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions

1 reference

12 December 2020

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?

1 reference

12 December 2020

10.1007/S00125-011-2190-9

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1030185189

0 references

1 reference